Angelini Ventures is the corporate venture capital arm of Angelini Industries, an Italian industrial group. Founded in 2022 with a €300 million evergreen fund commitment, Angelini Ventures invests at Series A and B stages in BioTech and Digital Health companies in Europe and North America. Brain health is a stated strategic priority, and the firm has made at least 6-7 neurotech-relevant investments. Portfolio includes CoMind (optical non-invasive brain monitoring, co-led £27M Series A and followed on in £60M round), Cadence Neuroscience (neuromodulation for drug-resistant epilepsy), Neumirna Therapeutics (RNA therapeutics for epilepsy and Parkinson's), Noctrix Health (neuromodulation for restless legs), Avation Medical (peripheral neuromodulation), and Therini Bio (neuroinflammation/Alzheimer's immunotherapy). The fund has explicitly described neurotech as a strategic priority and has an experienced board of directors across its neuro portfolio companies.